Moreover, a retrospective case-control study revealed that several factors, including advanced age, menopause, weight loss, cyst diameter equal to or exceeding 8.33cm, and the presence of solid areas on ultrasonography, were identified as noteworthy risk factors for EAOC (123)
Trastuzumab deruxtecan (T-DXd), which conjugates a topoisomerase I inhibitor to the trastuzumab scaffold, demonstrates high efficacy across HER2-expressing breast, gastric, and gynaecologic tumours
Nothing in this article is intended to be prescriptive or medical advice
From mental health to musculoskeletal and cardiovascular conditions, weight can influence how a person feels, moves and functions every day
their inclusion in subsequent work could deepen our understanding of how antioxidant mechanisms operate together in these interventions
They are separate medicines